News summary

Sleep and circadian disturbances in Alzheimer's disease: clinical assessment, treatable syndromes, and limits of biomarker inference

Source: Frontiers - Health • Published: 17 Oct 2026, 00:00

Summarized by Masters of Longevity from Frontiers - Health.

A narrative review links methods for assessing sleep and circadian disturbances in Alzheimer's disease to practical clinical decision points and treatment priorities.

Sleep and circadian disturbances in Alzheimer's disease: clinical assessment, treatable syndromes, and limits of biomarker inference
Key Takeaways
  • Randomized trials showing sleep-related clinical benefits remain separate from observational associations linking sleep measures to AD biomarkers.
Read the full article at Frontiers - Health ↗

Continue exploring

Recommended MoL Picks

MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.